TY - JOUR
T1 - PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat
T2 - Implications for the treatment of negative symptoms in schizophrenia
AU - Dyck, Bailee
AU - Guest, Kelly
AU - Sookram, Christal
AU - Basu, Dipannita
AU - Johnson, Rodney
AU - Mishra, Ram K.
PY - 2011/1
Y1 - 2011/1
N2 - The aim of this study was to investigate whether a potent analogue of the endogenous brain peptide l-prolyl- l-leucyl-glycinamide (PLG), (3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA), can prevent the induction of social withdrawal caused by sub-chronic treatment with the non-competitive NMDA (N-methyl- l-aspartate) receptor antagonist, MK-801.Results indicate that MK-801 (0.5. mg/kg) significantly decreased social interaction following sub-chronic treatment (7. days). Treatment with PAOPA (1. mg/kg) blocked the effects of MK-801, and increased the amount of time spent in social interaction in comparison to control animals. These results provide evidence for the development of peptidomimetic compounds for the treatment of social withdrawal and related negative symptoms associated with schizophrenia.
AB - The aim of this study was to investigate whether a potent analogue of the endogenous brain peptide l-prolyl- l-leucyl-glycinamide (PLG), (3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA), can prevent the induction of social withdrawal caused by sub-chronic treatment with the non-competitive NMDA (N-methyl- l-aspartate) receptor antagonist, MK-801.Results indicate that MK-801 (0.5. mg/kg) significantly decreased social interaction following sub-chronic treatment (7. days). Treatment with PAOPA (1. mg/kg) blocked the effects of MK-801, and increased the amount of time spent in social interaction in comparison to control animals. These results provide evidence for the development of peptidomimetic compounds for the treatment of social withdrawal and related negative symptoms associated with schizophrenia.
KW - Dopamine D2 receptor
KW - MK-801
KW - Non-competitive NMDA antagonist
KW - PAOPA
KW - Social interaction
UR - http://www.scopus.com/inward/record.url?scp=78650264988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650264988&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2010.09.025
DO - 10.1016/j.schres.2010.09.025
M3 - Article
C2 - 21036015
AN - SCOPUS:78650264988
SN - 0920-9964
VL - 125
SP - 88
EP - 92
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1
ER -